CÆLUM-CAPITAL
5.5.2022 11:02:12 CEST | Business Wire | Press release
Cælum Capital Limited, a specialist investor focused on premium beverage businesses, announced the acquisition of a majority stake in Compass Box Delicious Whisky Limited, a London-based premium Scotch whisky brand. Compass Box is ranked 4th in the “Top Trending Brands” in Scotch whisky segment by Drinks International.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005290/en/
Cælum was set up by Manish Rungta, an ex-Diageo executive with a background in private equity. Cælum has brought in Maurice Doyle as the new CEO of Compass Box to partner with the Founder, John Glaser, in the continued development of the business. A spirits industry veteran, Maurice Doyle brings nearly 30 years of marketing, commercial, and executive leadership experience from within the global alcoholic beverages sector. “I am delighted to be joining Compass Box. It is a brand that I have long admired as a pioneer within Scotch whisky. I have a huge amount of respect for John and what he has achieved,” says Doyle.
Founded in London in 2000, Compass Box is a reflection of Glaser’s personal vision for what the future of whisky making should be. John Glaser was named by Whisky Advocate as one of the “Thirty Innovators Who Shaped Today’s Whisky” and one of the only Two alive today. “With Maurice joining me at the helm, we are excited to double-down on our determination to democratise the enjoyment of Scotch whisky, to continue releasing products that reveal the creative art behind blending,” says Glaser, who has described the Compass Box mission as, “fighting…what I call the ‘single malt hegemony.’”
Cælum investment will be used to strengthen the balance sheet of the Company, acquire inventory, and build production facilities. Cælum will help facilitate the ambition of Compass Box to provide more opportunities to explore, experiment and innovate, with curiosity and creativity as its guiding principles. Manish Rungta, the Managing Partner at Cælum said, “We are excited to partner with Compass Box and it is representative of the innovative and pioneering brands within the beverage category that we would like to invest behind.”
Metric Point Capital, acted as the exclusive financial advisor and placement agent to Cælum. “We are thankful for the support of the Metric Point team during a very complex process and a crowded North American fundraising market. Metric Point brought highly technical skillsets and a tailored solution for this unique proprietary deal and we ended up being oversubscribed in our fundraising,” said Manish Rungta.
Corporate Partner Tom Braiden led the team at Brown Rudnick, an international law firm, which acted as exclusive legal advisor to Cælum.
Cælum Capital Limited
Cælum Capital Limited is based in London and is a specialist investor focused on investing in premium beverage businesses based in North America and Europe with a focus on alcoholic beverages. Cælum was founded by Manish Rungta, who is the Managing Partner of the firm and has extensive investment experience in the beverage sector, both alcoholic and non-alcoholic. Ex-SABMiller executive Mark Eames has joined Cælum as an Operating Partner and has extensive strategic, operational, and financial planning experience within the beverage sector. Cælum targets opportunities in the beverage segment with investment amounts ranging from US$50 – 200 million. For more information, please visit www.caelumcap.co.uk
.
Compass Box
Compass Box are Scotch whiskymakers. The word ‘whiskymaker’ is their word – it does not appear in a dictionary. For over 20 years they have been relentlessly focused on reinventing Scotch whisky, with every new blend designed to help make the world of whisky a more interesting place. Compass Box have won more awards for innovation than any other producer in Scotland because they are always experimenting. Always looking for sparks of creativity that will deliver something totally compelling, yet completely surprising. This vision motivates them as whiskymakers. Their blends are consistently rated equal to or better than the great single malts of Scotland by the most respected voices in the industry. For more information, please visit www.compassboxwhisky.com
or @CompassBoxWhiskyCo
on Instagram.
Metric Point Capital
(Member FINRA and SIPC)
Metric Point Capital is a boutique private capital advisory firm specializing in raising institutional capital for alternative investment managers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005290/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 19:09:00 CET | Press release
PriceRunner v. Google: Sweden’s Largest-Ever Civil Damages Claim Reaches Decision Stage; Klarna Provides Investor Update Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results whi
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 16:49:00 CET | Press release
New generative AI capabilities, enhanced incident detection, and expanded customer deployments mark a major evolution of the INRIX Traffic product family INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globall
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom